vs
eHealth, Inc.（EHTH）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
eHealth, Inc.的季度营收约是REPLIGEN CORP的1.6倍（$326.2M vs $197.9M），eHealth, Inc.净利率更高（26.7% vs 6.7%，领先20.0%），REPLIGEN CORP同比增速更快（13.6% vs 3.5%），REPLIGEN CORP自由现金流更多（$17.6M vs $-36.1M），过去两年eHealth, Inc.的营收复合增速更高（87.3% vs 14.4%）
eHealth, Inc.以eHealthInsurance品牌开展业务，是一家公开上市的健康保险在线交易平台，公司注册于特拉华州，总部位于加利福尼亚州圣克拉拉。该平台主要提供医疗保险相关计划，涵盖联邦医疗保险处方药计划、联邦医疗保险补充计划、优势计划等产品，同时也售卖个人健康保险产品，业务覆盖美国全部50个州及华盛顿特区。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
EHTH vs RGEN — 直观对比
营收规模更大
EHTH
是对方的1.6倍
$197.9M
营收增速更快
RGEN
高出10.1%
3.5%
净利率更高
EHTH
高出20.0%
6.7%
自由现金流更多
RGEN
多$53.6M
$-36.1M
两年增速更快
EHTH
近两年复合增速
14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $326.2M | $197.9M |
| 净利润 | $87.2M | $13.3M |
| 毛利率 | 55.3% | 52.5% |
| 营业利润率 | 38.7% | 9.0% |
| 净利率 | 26.7% | 6.7% |
| 营收同比 | 3.5% | 13.6% |
| 净利润同比 | -10.6% | 143.9% |
| 每股收益（稀释后） | $2.43 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EHTHRGEN
| Q4 25 | $326.2M | $197.9M | ||
| Q3 25 | $53.9M | $188.8M | ||
| Q2 25 | $60.8M | $182.4M | ||
| Q1 25 | $113.1M | $169.2M | ||
| Q4 24 | $315.2M | $174.1M | ||
| Q3 24 | $58.4M | $154.9M | ||
| Q2 24 | $65.9M | $154.1M | ||
| Q1 24 | $93.0M | $151.3M |
净利润EHTHRGEN
| Q4 25 | $87.2M | $13.3M | ||
| Q3 25 | $-31.7M | $14.9M | ||
| Q2 25 | $-17.4M | $14.9M | ||
| Q1 25 | $1.9M | $5.8M | ||
| Q4 24 | $97.5M | $-30.3M | ||
| Q3 24 | $-42.5M | $-654.0K | ||
| Q2 24 | $-28.0M | $3.3M | ||
| Q1 24 | $-17.0M | $2.1M |
毛利率EHTHRGEN
| Q4 25 | 55.3% | 52.5% | ||
| Q3 25 | -0.3% | 53.2% | ||
| Q2 25 | 31.1% | 50.0% | ||
| Q1 25 | 36.9% | 53.6% | ||
| Q4 24 | 52.0% | 26.1% | ||
| Q3 24 | -6.5% | 50.0% | ||
| Q2 24 | 28.7% | 49.8% | ||
| Q1 24 | 31.7% | 49.5% |
营业利润率EHTHRGEN
| Q4 25 | 38.7% | 9.0% | ||
| Q3 25 | -77.1% | 8.9% | ||
| Q2 25 | -37.9% | 7.6% | ||
| Q1 25 | 4.2% | 3.9% | ||
| Q4 24 | 35.7% | -17.7% | ||
| Q3 24 | -74.0% | -5.1% | ||
| Q2 24 | -42.5% | 1.0% | ||
| Q1 24 | -19.3% | 1.3% |
净利率EHTHRGEN
| Q4 25 | 26.7% | 6.7% | ||
| Q3 25 | -58.8% | 7.9% | ||
| Q2 25 | -28.6% | 8.2% | ||
| Q1 25 | 1.7% | 3.4% | ||
| Q4 24 | 30.9% | -17.4% | ||
| Q3 24 | -72.7% | -0.4% | ||
| Q2 24 | -42.5% | 2.2% | ||
| Q1 24 | -18.3% | 1.4% |
每股收益（稀释后）EHTHRGEN
| Q4 25 | $2.43 | $0.24 | ||
| Q3 25 | $-1.46 | $0.26 | ||
| Q2 25 | $-0.98 | $0.26 | ||
| Q1 25 | $-0.33 | $0.10 | ||
| Q4 24 | $2.93 | $-0.55 | ||
| Q3 24 | $-1.83 | $-0.01 | ||
| Q2 24 | $-1.33 | $0.06 | ||
| Q1 24 | $-0.96 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $73.7M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $591.6M | $2.1B |
| 总资产 | $1.3B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资EHTHRGEN
| Q4 25 | $73.7M | $767.6M | ||
| Q3 25 | $63.1M | $748.7M | ||
| Q2 25 | $65.9M | $708.9M | ||
| Q1 25 | $121.1M | $697.2M | ||
| Q4 24 | $39.2M | $757.4M | ||
| Q3 24 | $64.0M | $784.0M | ||
| Q2 24 | $126.3M | $809.1M | ||
| Q1 24 | $175.0M | $780.6M |
总债务EHTHRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EHTHRGEN
| Q4 25 | $591.6M | $2.1B | ||
| Q3 25 | $514.2M | $2.1B | ||
| Q2 25 | $554.9M | $2.1B | ||
| Q1 25 | $581.6M | $2.0B | ||
| Q4 24 | $588.4M | $2.0B | ||
| Q3 24 | $499.3M | $2.0B | ||
| Q2 24 | $548.9M | $2.0B | ||
| Q1 24 | $582.8M | $2.0B |
总资产EHTHRGEN
| Q4 25 | $1.3B | $2.9B | ||
| Q3 25 | $1.0B | $2.9B | ||
| Q2 25 | $1.1B | $2.9B | ||
| Q1 25 | $1.1B | $2.9B | ||
| Q4 24 | $1.2B | $2.8B | ||
| Q3 24 | $1.0B | $2.8B | ||
| Q2 24 | $1.0B | $2.9B | ||
| Q1 24 | $1.1B | $2.8B |
负债/权益比EHTHRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-35.9M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $-36.1M | $17.6M |
| 自由现金流率自由现金流/营收 | -11.1% | 8.9% |
| 资本支出强度资本支出/营收 | 0.0% | 4.1% |
| 现金转化率经营现金流/净利润 | -0.41× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $-27.6M | $93.9M |
8季度趋势，按日历期对齐
经营现金流EHTHRGEN
| Q4 25 | $-35.9M | $25.7M | ||
| Q3 25 | $-25.3M | $48.1M | ||
| Q2 25 | $-41.2M | $28.6M | ||
| Q1 25 | $77.1M | $15.0M | ||
| Q4 24 | $-27.7M | $39.2M | ||
| Q3 24 | $-29.3M | $49.3M | ||
| Q2 24 | $-32.2M | $42.2M | ||
| Q1 24 | $70.8M | $44.7M |
自由现金流EHTHRGEN
| Q4 25 | $-36.1M | $17.6M | ||
| Q3 25 | $-25.5M | $43.4M | ||
| Q2 25 | $-42.8M | $21.5M | ||
| Q1 25 | $76.8M | $11.4M | ||
| Q4 24 | $-28.3M | $33.6M | ||
| Q3 24 | $-30.3M | $42.3M | ||
| Q2 24 | $-32.4M | $37.4M | ||
| Q1 24 | $70.6M | $36.4M |
自由现金流率EHTHRGEN
| Q4 25 | -11.1% | 8.9% | ||
| Q3 25 | -47.4% | 23.0% | ||
| Q2 25 | -70.4% | 11.8% | ||
| Q1 25 | 67.9% | 6.8% | ||
| Q4 24 | -9.0% | 19.3% | ||
| Q3 24 | -51.8% | 27.3% | ||
| Q2 24 | -49.3% | 24.3% | ||
| Q1 24 | 75.9% | 24.0% |
资本支出强度EHTHRGEN
| Q4 25 | 0.0% | 4.1% | ||
| Q3 25 | 0.4% | 2.5% | ||
| Q2 25 | 2.6% | 3.9% | ||
| Q1 25 | 0.3% | 2.1% | ||
| Q4 24 | 0.2% | 3.2% | ||
| Q3 24 | 1.7% | 4.5% | ||
| Q2 24 | 0.4% | 3.1% | ||
| Q1 24 | 0.2% | 5.5% |
现金转化率EHTHRGEN
| Q4 25 | -0.41× | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | 39.55× | 2.57× | ||
| Q4 24 | -0.28× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EHTH
| Medicare | $282.7M | 87% |
| Other | $29.2M | 9% |
| Ancillaries | $7.9M | 2% |
| Commission Members Approved In Prior Periods | $3.8M | 1% |
| Small Business | $3.1M | 1% |
| Commission Revenue From Renewals | $2.4M | 1% |
RGEN
暂无分部数据
